Related Experiment Videos
Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer
1Department of Clinical Oncology, Royal Free Hospital Medical School, London, UK.
Abstract:
Alterations in the expression of genes affecting cell cycle progression occur in all human cancers. These may occur either by overexpression of genes such as cyclin D1, mutation of regulatory genes such as p16, or abrogation of checkpoints following DNA damage as in the cases of mutation or deletion of the p53 gene. Perturbation of the normal functions of these genes has a profound effect on cellular proliferation, differentiation and apoptosis. There is increasing evidence that such alterations may modulate the cellular response to treatment with chemotherapeutic agents. In many cases genetic alterations may induce resistance to drug treatment as in the case of mutations of the p53 gene. However, the deregulated expression of cell cycle genes may also increase sensitivity to treatment by directly altering the expression of the target for chemotherapeutic drugs as in the case of deletion of the retinoblastoma gene. It is crucial to understand the interactions between drug mechanisms of action and the genetic alterations in cancer to exploit potential areas in which the alterations found in tumors may constitute potential vulnerability.
Insights
Cancer cell cycle gene alterations impact chemotherapy response. Understanding these genetic changes can reveal vulnerabilities to cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- All human cancers exhibit alterations in cell cycle progression genes.
- These genetic changes include gene overexpression (e.g., cyclin D1), mutations (e.g., p16), and checkpoint abrogation (e.g., p53 gene mutations/deletions).
- Dysregulation of cell cycle genes profoundly affects cellular proliferation, differentiation, and apoptosis.
Purpose of the Study:
- To explore how genetic alterations in cell cycle genes influence cellular responses to chemotherapy.
- To identify how cancer-specific genetic changes can be leveraged as potential vulnerabilities in treatment strategies.
Main Methods:
- Review of existing literature on cell cycle gene alterations in human cancers.
- Analysis of the impact of specific gene mutations (p53, retinoblastoma) on drug resistance and sensitivity.
- Examination of the interplay between drug mechanisms and cancer genetics.
Main Results:
- Genetic alterations in cell cycle genes can induce resistance to chemotherapeutic agents (e.g., p53 mutations).
- Conversely, deregulated cell cycle gene expression can increase sensitivity to certain treatments (e.g., retinoblastoma gene deletion).
- These genetic modifications significantly modulate the efficacy of cancer therapies.
Conclusions:
- Understanding the relationship between drug action and cancer-specific genetic alterations is crucial.
- Exploiting these genetic vulnerabilities presents a promising avenue for developing more effective cancer treatments.
- Targeting cell cycle pathways based on tumor genetics may enhance therapeutic outcomes.